Abstract. Background/Aim: Lung cancer is the first cause of cancer related deaths in both males and females. Epithelialmesenchymal transition (EMT) is a reversible process by which epithelial cells transform to mesenchymal stem cells by losing their cell polarity and cell-to-cell adhesionLung cancer is the first cause of cancer-related deaths in both males and females. It is a fatal disease and most patients with lung cancer will die of their disease (1). Two main types of lung cancer exist: non-small-cell lung cancer (NSCLC) accounting for 85-90% of lung cancer cases, and small-cell lung cancer (SCLC), whose incidence seems to have decreased over the past decades (2). The current therapeutic approach for lung cancer includes surgical tumor removal, platinum-based chemotherapy, targeted therapy, immunotherapy and radiation therapy. Improvements in clinical and molecular understanding of the disease have resulted in novel therapeutic approaches. Multiple genetic and epigenetic abnormalities results in both oncogene activation [epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)] and inactivation of tumor-suppressor genes [transcription factor (p53) and retinoblastoma protein (RB)] (3). Moreover, angiogenesis seems to play an important role in the process of invasion and metastasis in lung cancer (4). Other molecular and cellular processes of lung cancer include genomic instability, escape from apoptosis, cell immortalization, abnormalities in immune response and epithelial-mesenchymal transition (EMT) (5-9).